Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer-initiating cells irrespective of tumor subtype

Cancer Gene Therapy

Volumn 20, Issue 5, 2013, Pages 282-289

  Cuddington, B P ^a   Dyer, A L ^a   Workenhe, S T ^a   Mossman, K L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Breast cancer therapy; Cancer initiating cells; Oncolytic virus

Indexed keywords

ONCOLYTIC VIRUS;

ARTICLE; BOVINE HERPES VIRUS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL RENEWAL; CELL TYPE; CELL VIABILITY; COLONY FORMING CELL; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VIVO STUDY; ONCOLYTIC BOVINE HERPESVIRUS TYPE 1; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TARGET CELL; VIRUS REPLICATION;

ANIMALS; BREAST NEOPLASMS; CATTLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HERPESVIRUS 1, BOVINE; HUMANS; MCF-7 CELLS; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

BOVINE HERPESVIRUS 1; HERPESVIRIDAE;

EID: 84878013929     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.18     Document Type: Article

References (50)

1. Cervantes-Garcia D, Ortiz-Lopez R, Mayek-Perez N, Rojas-Martinez A. Oncolytic virotherapy. Ann Hepatol 2008; 7: 34-45. (Pubitemid 351468535)
2. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254: 178-216. (Pubitemid 47126688)
3. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17: 199-207.
4. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771.
5. Geevarghese SK, Geller DA, de Haan HA, Horer M, Knoll AE, Mescheder A et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010; 21: 1119-1128.
6. Nakao A, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther 2011; 18: 167-175.
7. Campadelli-Fiume G, Cocchi F, Menotti L, Lopez M. The novel receptors that mediate the entry of herpes simplex viruses and animal alphaherpesviruses into cells. Rev Med Virol 2000; 10: 305-319.
8. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998; 280: 1618-1620. (Pubitemid 28277708)
9. Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C, Lustenberger P et al. Overexpression of the CD155 gene in human colorectal carcinoma. Gut 2001; 49: 236-240. (Pubitemid 32675118)
10. Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C, Simeone M et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 2004; 4: 73.
11. Hushur O, Takashima Y, Matsumoto Y, Otsuka H. Restriction of bovine herpesvirus 1 (BHV-1) growth in non-permissive cells beyond the expression of immediate early genes. J Vet Med Sci 2004; 66: 453-455. (Pubitemid 41380319)
12. Rodrigues R, Cuddington B, Mossman K. Bovine herpesvirus type 1 as a novel oncolytic virus. Cancer Gene Ther 2009; 17: 344-355.
13. Abril C, Engels M, Liman A, Hilbe M, Albini S, Franchini M et al. Both viral and host factors contribute to neurovirulence of bovine herpesviruses 1 and 5 in interferon receptor-deficient mice. J Virol 2004; 78: 3644-3653. (Pubitemid 38568304)
14. Cheng X, O'Neill HC. Oncogenesis and cancer stem cells: current opinions and future directions. J Cell Mol Med 2009; 13: 4377-4384.
15. Hemmings C. . The elaboration of a critical framework for understanding cancer: the cancer stem cell hypothesis. Pathology 2010; 42: 105-112.
16. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317: 337. (Pubitemid 47106366)
17. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev 2005; 5: 275-284. (Pubitemid 40488633)
18. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. . Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-1806. (Pubitemid 26134320)
19. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008; 268: 1-9.
20. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-14233. (Pubitemid 39305058)
21. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2007; 104: 16158-16163. (Pubitemid 350099378)
22. Han JS, Crowe DL. Tumor initiating cancer stem cells from human breast cancer cell lines. Int J Oncol 2009; 34: 1449-1453.
23. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-6219.
24. Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res 2008; 68: 2419-2426. (Pubitemid 351521817)
25. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008; 122: 298-304. (Pubitemid 350234715)
26. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
27. Cripe TP, Wang PY, Marcato P, Mahller YY, Lee PW. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 2009; 17: 1677-1682.
28. Patel SA, Ndabahaliye A, Lim PK, Milton R, Rameshwar P. Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer (London) 2010; 2: 1-11.
29. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther 2009; 17: 972-979.
30. Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M et al. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res 2008; 68: 5533-5539.
31. Eriksson M, Guse K, Bauerschmitz G, Virkkunen P, Tarkkanen M, Tanner M et al. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther 2007; 15: 2088-2093. (Pubitemid 350148923)
32. Lal R, Harris D, Postel-Vinay S, de Bono J. Reovirus: rationale and clinical trial update. Curr Opin Mol Ther 2009; 11: 532-539.
33. Dey M, Ulasov IV, Tyler MA, Sonabend AM, Lesniak MS. Cancer stem cells: the final frontier for glioma virotherapy. Stem Cell Rev 2011; 7: 119-129.
34. Ahtiainen L, Mirantes C, Jahkola T, Escutenaire S, Diaconu I, Osterlund P et al. Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus. PLoS One 2010; 5: e13859.
35. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080. (Pubitemid 32758077)
36. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
37. Fernandez AF, Esteller M. Viral epigenomes in human tumorigenesis. Oncogene 2010; 29: 1405-1420.
38. Niller HH, Wolf H, Minarovits J. . Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol 2009; 19: 158-164.
39. Adhya D, Basu A. Epigenetic modulation of host: new insights into immune evasion by viruses. J Biosci 2010; 35: 647-663.
40. Paschos K, Allday MJ. Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol 2010; 18: 439-447.
41. Cullen BR. Viruses and microRNAs: RISCy interactions with serious consequences. Genes Dev 2011; 25: 1881-1894.
42. Lu F, Stedman W, Yousef M, Renne R, Lieberman PM. Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J Virol 2010; 84: 2697-2706.
43. Liu C, Tang DG. MicroRNA regulation of cancer stem cells. Cancer Res 2011; 71: 5950-5954.
44. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011; 21: 502-517.
45. Yamada Y, Watanabe A. Epigenetic codes in stem cells and cancer stem cells. Adv Genet 2010; 70: 177-199.
46. Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011; 19: 1008-1016.
47. Mastrangelo MJ, Maguire HC, Lattime EC. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv Exp Med Biol 2000; 465: 391-400. (Pubitemid 32193350)
48. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
49. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D et al. Comparative oncogenomics identifies breast tumors enriched in functional tumorinitiating cells. Proc Natl Acad Sci USA 2012; 109: 2778-2783.
50. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML et al. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439: 84-88. (Pubitemid 43053633)